Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Holmlund

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Seminars in Oncology|April 1, 1997
Antigen-specific agents in developmentM Sznol, J Holmlund
Cancer Investigation|October 19, 2000
Antisense approaches for the treatment of cancerB P Monia, J Holmlund, F A Dorr
Antisense & Nucleic Acid Drug Development|May 21, 1998
Antisense oligonucleotides as inhibitors of genes that regulate AP-1: pharmacology and clinical developmentN M Dean, R A McKay, J Holmlund
Journal of Acquired Immune Deficiency Syndromes|January 1, 1990
Low-dose multidrug chemotherapy plus Pneumocystis carinii pneumonia prophylaxis for HIV-related Kaposi's sarcomaP G Shields, F Dawkins, J Holmlund, et al.
International Journal of Oncology|May 11, 2011
Phase i/ii trial of 5-Fluorouracil, leucovorin, Zidovudine and dipyridamole for patients with metastatic colorectal-cancer, renal-cell carcinoma and malignant-melanomaW Sharfman, W Urba, J Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)P J O'Dwyer, J P Stevenson, M Gallagher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)J P Stevenson, K S Yao, M Gallagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancerB L Gause, M Sznol, W C Kopp, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Seminars in Oncology|April 1, 1997
Antigen-specific agents in developmentM Sznol, J Holmlund
Cancer Investigation|October 19, 2000
Antisense approaches for the treatment of cancerB P Monia, J Holmlund, F A Dorr
Antisense & Nucleic Acid Drug Development|May 21, 1998
Antisense oligonucleotides as inhibitors of genes that regulate AP-1: pharmacology and clinical developmentN M Dean, R A McKay, J Holmlund
Journal of Acquired Immune Deficiency Syndromes|January 1, 1990
Low-dose multidrug chemotherapy plus Pneumocystis carinii pneumonia prophylaxis for HIV-related Kaposi's sarcomaP G Shields, F Dawkins, J Holmlund, et al.
International Journal of Oncology|May 11, 2011
Phase i/ii trial of 5-Fluorouracil, leucovorin, Zidovudine and dipyridamole for patients with metastatic colorectal-cancer, renal-cell carcinoma and malignant-melanomaW Sharfman, W Urba, J Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)P J O'Dwyer, J P Stevenson, M Gallagher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)J P Stevenson, K S Yao, M Gallagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancerB L Gause, M Sznol, W C Kopp, et al.
Pageof 2